Ear, nose and throat diseases Ear, Nose and Throat
Conditions
Interventions
group 2 rocuronium 0.6 mg.kg-1
group 3 atracurium 0.45 mg.kg-1
group 4 suxamethonium 1.0 mg.kg-1
and group 5 mivacurium 0.16 mg.kg-1.
Phase I: The patients will be allocated randomly to one of four groups. Group one will have the adductor pollicis twitch reduced by 25%, group two 50%, group three 75% and group four 90%.
Sponsors
NHS R&D Regional Programme Register - Department of Health (UK)
Eligibility
Inclusion criteria
Inclusion criteria: Phase 1: 40 patients will be studied in this randomised crossover study. All patients will be scheduled to undergo elective surgery which will require the use of nondepolarizing muscle relaxants. Phase 2: American Society of Anesthesiologists (ASA) 1&2 patients will be studied initially. Inclusion and exclusion criteria and patient monitoring will be as for Phase 1. Patients will then be allocated randomly to receive one of five muscle relaxants (10 per group). If numbers prove insufficient, further patients will be recruited, in groups of 25 (5 per group).
Exclusion criteria
Exclusion criteria: Any patient with a history of regurgitation, dyspepsia or neuromuscular disease or who is taking any medication that may interfere with neuromuscular function will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Interim and final reports for review by NHS Executive Trent | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed